URGN
UroGen Pharma·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About URGN
Urogen Pharma Ltd.
A biotech company that develops novel therapies for urothelial cancer treatment only in a water-based formulation
400 Alexander Park, Princeton, NJ, 08540
Develops hydrogel-based therapies for urothelial cancers.
Urogen Pharma Ltd. was established under the laws of the State of Israel in April 2004 as TheraCoat Ltd. In September 2015, the company changed its name to Urogen Pharma Ltd.. The company is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care in urological pathology.
Company Financials
EPS
URGN has released its 2026 Q2 earnings. EPS was reported at -0.28, versus the expected -0.27, missing expectations. The chart below visualizes how URGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
URGN has released its 2026 Q2 earnings report, with revenue of 72.46M, reflecting a YoY change of 199.22%, and net profit of -14.35M, showing a YoY change of 71.26%. The Sankey diagram below clearly presents URGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
